CureVac’s German Owner Rejects US Coronavirus Vaccine Grab
Made In Germany For the World Is Hopp’s Vision
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
You may also be interested in...
Governments around Europe take action to shut places of work and schools and impose new border restrictions, as death toll rises in Italy, France and Spain.
The US government has a routine approach for negotiating single-seller/single-buyer contracts, but drug pricing politics and public fears of coronavirus will likely complicate any purchasing talks with a sponsor, should an effective vaccine or therapeutic emerge.
Trump Administration officials pledge support for basic science and expedited regulatory review while emphasizing the benefits that could be offered by drugs in the near term until a vaccine is developed.